Related content

Superior antitumor activity of trastuzumab combined with capecitabine plus oxaliplatin in a human epidermal growth factor receptor 2-positive human gastric cancer xenograft model

By              

Molecular and Clinical Oncology, Vol. 3, Iss. 5, 2015-01 ,pp. : 987-994

Science Publishers

Access to resources Recommend Favorite

Factors affecting disease-free survival in patients with human epidermal growth factor receptor 2-positive breast cancer who receive adjuvant trastuzumab

By                      

Molecular and Clinical Oncology, Vol. 3, Iss. 5, 2015-01 ,pp. : 1109-1112

Science Publishers

Access to resources Recommend Favorite

Adding hormonal therapy to chemotherapy and trastuzumab improves prognosis in patients with hormone receptor-positive and human epidermal growth factor receptor 2-positive primary breast cancer

By Hayashi Naoki  

Breast Cancer Research and Treatment, Vol. 137, Iss. 2, 2013-01 ,pp. : 523-531

Springer Publishing Company

Access to resources Recommend Favorite

Lapatinib combined with neoadjuvant paclitaxel-trastuzumab-based chemotherapy in patients with human epidermal growth factor receptor 2-positive breast cancer: A meta-analysis of randomized controlled trials

By  

Oncology Letters, Vol. 9, Iss. 3, 2015-01 ,pp. : 1351-1358

Spandidos Publications

Access to resources Recommend Favorite

Dual human epidermal growth factor receptor 2 blockade for the treatment of HER2-positive breast cancer

By Alvarez Ricardo  

Breast Cancer, Vol. 20, Iss. 2, 2013-04 ,pp. : 103-110

Springer Publishing Company

Access to resources Recommend Favorite